Biotech is back! But it’s not quite as simple as that.
After years of volatility, the sector heads into 2026 with a renewed sense of possibility, buoyed by resurgent markets, intensified metabolic health competition, and the first tremors of a looming $300bn patent cliff.
Our 2026 Preview Infographic distils the key report findings to highlight the trends set to shape the year ahead; from top selling therapies and major launches, to shifting regulatory winds and the next wave of clinical innovation.
Key Highlights:
- Top Selling Drugs to Watch. With Keytruda, Mounjaro and Skyrizi continuing their blockbuster trajectories, oncology and immunology remain the industry’s commercial anchors.
- Who Leads Big Pharma in 2026? Eli Lilly, AbbVie and Roche dominate the rankings, supported by robust franchises and smart lifecycle management.
- Feeling the Patent Pain The peak of the patent cliff isn’t here yet — but the first big cracks are already forming.
- 2026’s Big Potential Launches What are the year’s most anticipated approvals that could reshape competitive dynamics across metabolic diseases, oncology and advanced therapies?
- Regulatory Turbulence at the FDA. The FDA faces both opportunities and challenges. While accelerated review vouchers offer unusual speed, political intervention threatens stability in areas like vaccines.
Download the infographic now to explore the data shaping tomorrow’s pharma strategies.
